This study was aimed to observe the antibacterial activity and bactericidal action ofC.albicans in vitro, and the effects of curing monilial vaginitis mouse by extraction of globeflower residue fermentation (EGRF) in vivo.In vitrostudy, test tube method as well as plate method were used to determine the minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) ofC.albicansrespectively.In vivo, mouse were devided into normal controlled group,C. albicans vaginitis model group (Model), Model + EGRF (40, 80, 160 mg?kg-1) group, and fluconazole group (20 mg?kg-1). All drugs were vaginal delivery once a day with continuous administration for seven days. Then vulva inflammation, negative rate of vaginal discharge, microbial load of vaginal lavage and the pathological changes of vaginal mucosa were observed. After the treatment of EGRF, the MIC and MBC of Candida albicans were 0.31 mg?mL-1 and 1.25 mg?mL-1, respectively, while the potency unit ratios between EGRF and fluconazole of MIC and MBC were 2 to 1 and 1 to 1, respectively. In comparison with Model, vulva inflammation of Model + EGRF gourp and fluconazole group was improved, whileC. albicanscount in vaginal secretions of these two groups were decreased, the overcast rate ofC. albicansof vaginal douche was increased, and pathological changes of vaginal mucosa were also improved in the two groups, which were in dose-dependent manners. And high dose Model + EGRF group was close to fluconazole group. In conclusion, EGRF had obvious inhibitory effect onC. albicans in vitro. It also had a better therapeutic effect onC. albicans vaginitis mouse.